{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:34:34Z","timestamp":1763141674780,"version":"build-2065373602"},"reference-count":84,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T00:00:00Z","timestamp":1635984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJERPH"],"abstract":"<jats:p>Myasthenia Gravis (MG) is a chronic, life-lasting condition that requires high coordination among different professionals and disciplines. The diagnosis of MG is often delayed and sometimes misdiagnosed. The goal of the care pathway (CP) is to add value to healthcare reducing unnecessary variations. The quality of the care received by patients affected with MG could benefit from the use of CP. We conducted a study aimed to define an inclusive, comprehensive, and multidisciplinary CP for the diagnosis, treatment, and care of MG. The development of the model CP, key interventions, and process indicators is based on the literature review and 85 international MG experts were involved in their evaluation, expressing a judgment of relevance through the Delphi study. 60 activities are included in the model CP and evaluated by the MG experts were valid and feasible. The 60 activities were then translated into 14 key interventions and 24 process indicators. We believe that the developed model CP will help for MG patients to have a timely diagnosis and high-quality, accessible, and cost-effective treatments and care. We also believe that the development of model CPs for other rare diseases is feasible and could aid in the integration of evidence-based knowledge into clinical practice.<\/jats:p>","DOI":"10.3390\/ijerph182111591","type":"journal-article","created":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T09:11:32Z","timestamp":1636017092000},"page":"11591","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Development of a Model Care Pathway for Myasthenia Gravis"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4298-1305","authenticated-orcid":false,"given":"Anil babu","family":"Payedimarri","sequence":"first","affiliation":[{"name":"Department of Translational Medicine (DIMET), Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"},{"name":"European Pathway Association, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9273-9114","authenticated-orcid":false,"given":"Matteo","family":"Ratti","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine (DIMET), Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"},{"name":"European Pathway Association, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0117-3432","authenticated-orcid":false,"given":"Riccardo","family":"Rescinito","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine (DIMET), Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"},{"name":"European Pathway Association, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Vasile","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine (DIMET), Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"},{"name":"European Pathway Association, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4966-3879","authenticated-orcid":false,"given":"Deborah","family":"Seys","sequence":"additional","affiliation":[{"name":"European Pathway Association, 3000 Leuven, Belgium"},{"name":"Department of Public Health and Primary Care, Leuven Institute for Healthcare Policy, KU Leuven, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Dumas","sequence":"additional","affiliation":[{"name":"UCB Pharma, 1630 Bulle, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kris","family":"Vanhaecht","sequence":"additional","affiliation":[{"name":"European Pathway Association, 3000 Leuven, Belgium"},{"name":"Department of Public Health and Primary Care, Leuven Institute for Healthcare Policy, KU Leuven, 3000 Leuven, Belgium"},{"name":"Department of Quality Management, University Hospitals Leuven, University of Leuven, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Panella","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine (DIMET), Universit\u00e0 del Piemonte Orientale, 28100 Novara, Italy"},{"name":"European Pathway Association, 3000 Leuven, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1741-7015-8-31","article-title":"What is a clinical pathway? Development of a definition to inform the debate","volume":"8","author":"Kinsman","year":"2010","journal-title":"BMC Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1258\/jicp.2010.010019","article-title":"An overview on the history and concept of care pathways as complex interventions","volume":"14","author":"Vanhaecht","year":"2010","journal-title":"Int. J. Care Pathw."},{"key":"ref_3","unstructured":"Vanhaecht, K. (2007). The Impact of Clinical Pathways on the Organisation of Care Processes. [Ph.D. Dissertation, The Katholieke Universiteit Leuven (KU Leuven)]."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Schrijvers, G., van Hoorn, A., and Huiskes, N. (2012). The Care Pathway: Concepts and Theories: An introduction. Int. J. Integr. Care, (Published Online First: 2011).","DOI":"10.5334\/ijic.812"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0140-6736(03)14546-1","article-title":"From best evidence to best practice: Effective implementation of change in patients\u2019 care","volume":"362","author":"Grol","year":"2003","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/ACM.0000000000003122","article-title":"Defining and implementing value-based health care: A strategic framework","volume":"95","author":"Teisberg","year":"2020","journal-title":"Acad. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1377\/hlthaff.27.3.759","article-title":"The triple aim: Care, health, and cost","volume":"27","author":"Berwick","year":"2008","journal-title":"Health Aff."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0180398","article-title":"Better organized care via care pathways: A multicenter study","volume":"12","author":"Seys","year":"2017","journal-title":"PLoS ONE"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Rutman, L., Klein, E.J., and Brown, J.C. (2017). Clinical pathway produces sustained improvement in acute gastroenteritis care. Pediatrics, 140.","DOI":"10.1542\/peds.2016-4310"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.hpb.2017.04.015","article-title":"The impact of a clinical pathway on patient postoperative recovery following pancreaticoduodenectomy","volume":"19","author":"Tremblay","year":"2017","journal-title":"HPB"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1542\/hpeds.2016-0150","article-title":"Nurse-driven clinical pathway for inpatient asthma: A randomized controlled trial","volume":"7","author":"Pound","year":"2017","journal-title":"Hosp. Pediatr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1744-1609.2011.00223.x","article-title":"Clinical pathways: Effects on professional practice, patient outcomes, length of stay and hospital costs","volume":"9","author":"Rotter","year":"2011","journal-title":"Int. J. Evid. Based Healthc."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/2151458516645633","article-title":"Effectiveness of a multidisciplinary clinical pathway for elderly patients with hip fracture","volume":"7","author":"Kalmet","year":"2016","journal-title":"Geriatr. Orthop. Surg. Rehabil."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-7-32","article-title":"Effects of clinical pathways in the joint replacement: A meta-analysis","volume":"7","author":"Barbieri","year":"2009","journal-title":"BMC Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jval.2015.05.008","article-title":"Rare disease terminology and definitions-A systematic global review: Report of the ISPOR rare disease special interest group","volume":"18","author":"Hughes","year":"2015","journal-title":"Value Health"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s00415-009-5318-9","article-title":"Unsatisfactory outcomes in myasthenia gravis: Influence by care providers","volume":"257","author":"Dunand","year":"2010","journal-title":"J. Neurol."},{"key":"ref_17","unstructured":"(2021, July 22). Clinical Overview of MG. Available online: https:\/\/myasthenia.org\/Professionals\/Clinical-Overview-of-MG."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Carr, A.S., Cardwell, C.R., McCarron, P.O., and Conville, J.M. (2010). A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol., 10.","DOI":"10.1186\/1471-2377-10-46"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000431036","article-title":"Geographical distribution of myasthenia gravis in northern Europe\u2014Results from a population-based study from two countries","volume":"44","author":"Boldingh","year":"2015","journal-title":"Neuroepidemiology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1136\/jnnp.74.8.1105","article-title":"Evidence of underdiagnosis of myasthenia gravis in older people","volume":"74","author":"Vincent","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_21","first-page":"654","article-title":"Misdiagnosis of myasthenia gravis and subsequent clinical implication: A case report and review of literature","volume":"12","author":"Nandhagopal","year":"2012","journal-title":"Sultan Qaboos Univ. Med. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/omcr\/omy052","article-title":"Misdiagnosis of myasthenia gravis presenting with tongue and palatal weakness","volume":"2018","author":"Marshal","year":"2018","journal-title":"Oxf. Med. Case Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","article-title":"Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals","volume":"72","author":"Alshekhlee","year":"2009","journal-title":"Neurology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/CND.0b013e31822c34dd","article-title":"Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: An acute hospital cost comparison study","volume":"13","author":"Heatwole","year":"2011","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/ene.12359","article-title":"EFNS\/ENS Guidelines for the treatment of ocular myasthenia","volume":"21","author":"Kerty","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: Association of british neurologists\u2019 management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Pract. Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42466-019-0023-3","article-title":"SOP myasthenic crisis","volume":"1","author":"Stetefeld","year":"2019","journal-title":"Neurol. Res. Pract."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: Clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1503\/cmaj.090449","article-title":"AGREE II: Advancing guideline development, reporting and evaluation in health care","volume":"182","author":"Brouwers","year":"2010","journal-title":"Can. Med. Assoc. J."},{"key":"ref_30","unstructured":"(2020, September 01). AGREE II Training Tools. Available online: https:\/\/www.agreetrust.org\/resource-centre\/agree-ii\/agree-ii-training-tools\/."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1111\/j.1468-1331.2004.00867.x","article-title":"Guidance for the preparation of neurological management guidelines by EFNS scientific task forces: Revised recommendations 2004","volume":"9","author":"Brainin","year":"2004","journal-title":"Eur. J. Neurol."},{"key":"ref_32","unstructured":"(2020, November 30). io.draw. Available online: https:\/\/app.diagrams.net\/."},{"key":"ref_33","unstructured":"(2020, September 05). M3 Global Research. Available online: https:\/\/www.m3globalresearch.com\/."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Balakrishnan, N., Colton, T., Everitt, B., Piegorsch, W., Ruggeri, F., and Teugels, J.L. (2014). Delphi Method. Wiley StatsRef: Statistics Reference Online, Wiley\u2014Blackwell.","DOI":"10.1002\/9781118445112"},{"key":"ref_35","unstructured":"(2021, October 24). Non-Response Bias: A Bias That Occurs Due to Systematic Differences between Responders and Non-Responders. Available online: https:\/\/catalogofbias.org\/biases\/non-response-bias\/."},{"key":"ref_36","unstructured":"(2021, April 06). SoGoSurvey. Available online: https:\/\/www.sogosurvey.com\/help\/how-to-calculate-overall-score-in-omni\/."},{"key":"ref_37","first-page":"341","article-title":"The 7-phase method to design, implement and evaluate care pathways","volume":"2","author":"Vanhaecht","year":"2012","journal-title":"Int. J. Pers. Cent. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1745-6215-13-229","article-title":"Eight-step method to build the clinical content of an evidence-based care pathway: The case for COPD exacerbation","volume":"13","author":"Lodewijckx","year":"2012","journal-title":"Trials"},{"key":"ref_39","unstructured":"(2021, March 01). European Pathway Association. Available online: https:\/\/e-p-a.org\/."},{"key":"ref_40","unstructured":"(2020, November 05). The Joint Commission. Available online: https:\/\/manual.jointcommission.org\/releases\/TJC2022A\/MIF0344.html."},{"key":"ref_41","unstructured":"(2020, November 02). Agency for Healthcare Research and Quality, Available online: https:\/\/qualityindicators.ahrq.gov\/."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"ref_43","first-page":"294","article-title":"Evidence-based guideline update: Plasmapheresis in neurologic disorders","volume":"77","author":"Freeman","year":"2011","journal-title":"Neurology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1212\/WNL.0b013e31824de293","article-title":"Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders","volume":"78","author":"Patwa","year":"2012","journal-title":"Neurology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/mus.24745","article-title":"Repetitive nerve stimulation and single-fiber electromyography in the evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome","volume":"52","author":"Gilchrist","year":"2015","journal-title":"Muscle Nerve"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.55.1.7","article-title":"Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"55","author":"Gronseth","year":"2000","journal-title":"Neurology"},{"key":"ref_47","unstructured":"Fowler, S.B. (2014). Care of The Patient with Myasthenia Gravis, American Association of Neuroscience Nurses."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","article-title":"Guidelines for treatment of autoimmune neuromuscular transmission disorders","volume":"17","author":"Skeie","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/j.1468-1331.2008.02246.x","article-title":"EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases","volume":"15","author":"Elovaara","year":"2008","journal-title":"Eur. J. Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/jnnp-2013-305572","article-title":"Myasthenia in pregnancy: Best practice guidelines from a UK multispecialty working group","volume":"85","author":"Norwood","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/mus.21433","article-title":"Consensus statement: The use of intravenous immunoglobulin in the treatment of neuromuscular conditions","volume":"40","author":"Donofrio","year":"2009","journal-title":"Muscle Nerve"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/cen3.12180","article-title":"Japanese clinical guidelines for myasthenia gravis: Putting into practice","volume":"6","author":"Murai","year":"2015","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1590\/0004-282X20130108","article-title":"The myasthenic patient in crisis: An update of the management in Neurointensive care unit","volume":"71","author":"Godoy","year":"2013","journal-title":"Arq. Neuropsiquiatr."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","article-title":"Treatment of myasthenia gravis","volume":"36","author":"Farmakidis","year":"2018","journal-title":"Neurol. Clin."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","article-title":"Myasthenia gravis: Subgroup classification and therapeutic strategies","volume":"14","author":"Gilhus","year":"2015","journal-title":"Lancet Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_57","first-page":"1","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/pnp.315","article-title":"Diagnosis and management of myasthenia gravis","volume":"18","author":"Sathasivam","year":"2014","journal-title":"Prog. Neurol. Psychiatry"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"86","DOI":"10.17925\/ENR.2018.13.2.86","article-title":"Myasthenia gravis\u2014A review of current therapeutic options","volume":"13","author":"Jacob","year":"2018","journal-title":"Eur. Neurol. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3988\/jcn.2011.7.4.173","article-title":"Treatment of myasthenia gravis based on its immunopathogenesis","volume":"7","author":"Kim","year":"2011","journal-title":"J. Clin. Neurol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: Emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/CND.0000000000000156","article-title":"Outcome measures in myasthenia gravis: Incorporation into clinical practice","volume":"18","author":"Muppidi","year":"2017","journal-title":"J. Clin. Neuromuscul. Dis"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Howard, J.F. (2009). Myasthenia Gravis: A Manual for the Health Care Provider, Myasthenia Gravis Foundation of America. [1st ed.].","DOI":"10.1016\/B978-1-4160-4417-8.50141-8"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/WCO.0000000000000473","article-title":"Myasthenia gravis: New developments in research and treatment","volume":"30","author":"Evoli","year":"2017","journal-title":"Curr. Opin. Neurol."},{"key":"ref_65","unstructured":"(2020, November 02). Myasthenia Gravis: Delphi Study. Available online: https:\/\/www.sogosurvey.com\/preview.aspx?k=YsQUWYUsUV&status=preview."},{"key":"ref_66","unstructured":"De Luc, K. (2000). Developing Care Pathways, National Pathways Association, Radcliffe Medical Press."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1183\/13993003.01170-2015","article-title":"A review of national guidelines for management of COPD in Europe","volume":"47","author":"Miravitlles","year":"2016","journal-title":"Eur. Respir. J."},{"key":"ref_68","first-page":"391","article-title":"Developing evidence-based practice guidelines and pathways: The Experience at the local hospital level","volume":"22","author":"Greengold","year":"1996","journal-title":"Jt. Comm. J. Qual. Improv."},{"key":"ref_69","first-page":"54","article-title":"The care process organization triangle: A framework to better understand how clinical pathways work","volume":"11","author":"Vanhaecht","year":"2007","journal-title":"J. Integr. Care Pathw."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/ene.13536","article-title":"ECTRIMS\/EAN guideline on the pharmacological treatment of people with multiple sclerosis","volume":"25","author":"Montalban","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/bmj.g5701","article-title":"Multiple sclerosis: Summary of NICE guidance","volume":"349","author":"Perry","year":"2014","journal-title":"BMJ"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Rotter, T., Kinsman, L., James, E., Machotta, A., and Steyerberg, E.W. (2012). The Quality of the evidence base for clinical pathway effectiveness: Room for improvement in the design of evaluation trials. BMC Med., 12.","DOI":"10.1186\/1471-2288-12-80"},{"key":"ref_73","first-page":"66","article-title":"The development and implementation of an integrated multidisciplinary clinical pathway","volume":"24","author":"Ramos","year":"1997","journal-title":"J. Wound Ostomy Cont. Nurs."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"112","DOI":"10.5455\/msm.2012.24.112-120","article-title":"Comparisons of health care systems in the United States, Germany and Canada","volume":"24","author":"Ridic","year":"2012","journal-title":"Mater Socio Medica"},{"key":"ref_75","unstructured":"Jakubowski, E., and Busse, R. (1998). Health Care Systems in the EU: A Comparative Study, European Parliament."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","article-title":"Economic costs of myasthenia gravis: A Systematic Review","volume":"38","author":"Landfeldt","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1542\/pir.2016-0012","article-title":"Allocation of health care resources: Principles for decision-making","volume":"38","author":"Newton","year":"2017","journal-title":"Pediatr. Rev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1158\/1078-0432.CCR-17-1609","article-title":"Clinical pathways: Recommendations for putting patients at the center of value-based care","volume":"23","author":"Abrahams","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.socscimed.2012.02.060","article-title":"Care pathways lead to better teamwork: Results of a systematic review","volume":"75","author":"Deneckere","year":"2012","journal-title":"Soc. Sci. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/MLR.0b013e3182763312","article-title":"Better interprofessional teamwork, higher level of organized care, and lower risk of burnout in acute health care teams using care pathways: A cluster randomized controlled trial","volume":"51","author":"Deneckere","year":"2013","journal-title":"Med. Care"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/intqhc\/mzy197","article-title":"Better hospital context increases success of care pathway implementation on achieving greater teamwork: A multicenter study on STEMI care","volume":"31","author":"Aeyels","year":"2019","journal-title":"Int. J. Qual. Health Care"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Ellershaw, J., and Wilkinson, S. (2003). What about care pathways?. Care of the Dying: A Pathway to Excellence, Oxford University Press.","DOI":"10.1093\/acprof:oso\/9780198509332.001.0001"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-020-01631-1","article-title":"RarERN Path: A methodology towards the optimisation of patients\u2019 care pathways in rare and complex diseases developed within the European Reference Networks","volume":"15","author":"Talarico","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s12687-021-00520-9","article-title":"Rare disease care pathways in the EU: From odysseys and labyrinths towards highways","volume":"12","author":"Tumiene","year":"2021","journal-title":"J. Community Genet."}],"container-title":["International Journal of Environmental Research and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/21\/11591\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:25:45Z","timestamp":1760167545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-4601\/18\/21\/11591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":84,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["ijerph182111591"],"URL":"https:\/\/doi.org\/10.3390\/ijerph182111591","relation":{},"ISSN":["1660-4601"],"issn-type":[{"type":"electronic","value":"1660-4601"}],"subject":[],"published":{"date-parts":[[2021,11,4]]}}}